Inactive Instrument

Amryt Pharma plc

AMYT

US03217L1061

Amryt Pharma plc Provides Revenue Guidance for the Full Year 2022

March 09, 2022 at 12:00 pm

Amryt Pharma plc provided revenue guidance for the full year 2022. For the year, Company expects revenue in the range of $260 million to $270 million which represents growth of 17% to 21% on Fiscal Year 2021.

Latest news about Amryt Pharma plc

Amryt Pharma plc(NasdaqGS:AMYT) dropped from S&P Global BMI Index	13/04/23	CI
Amryt Pharma plc(NasdaqGS:AMYT) dropped from NASDAQ Composite Index	12/04/23	CI
Chiesi Farmaceutici S.p.A. completed the acquisition of Amryt Pharma plc from Athyrium Capital Management, LP, Highbridge Capital Management, LLC, Joe Wiley, Rory Nealon, Ray Stafford and others.	11/04/23	CI
Amryt Pharma's Shareholders Approve Acquisition by Chiesi Farmaceutici	22/03/23	MT
Amryt Pharma plc’s Equity Buyback announced on March 9, 2022, has expired.	07/03/23	CI
HC Wainwright Downgrades Amryt Pharma to Neutral From Buy, Cuts Price Target to $14.50 From $18	18/01/23	MT
Maxim Group Downgrades Amryt Pharma to Hold From Buy	10/01/23	MT
Cantor Fitzgerald Downgrades Amryt Pharma to Neutral From Overweight, Adjusts Price Target to $14.75 From $25	10/01/23	MT
Canaccord Genuity Downgrades Amryt Pharma to Hold From Buy, Adjusts Price Target to $17 From $19	10/01/23	MT
Sector Update: Health Care Stocks Largely Struggle Monday	09/01/23	MT
Top Midday Gainers	09/01/23	MT
Sector Update: Health Care Stocks Struggling to Begin New Week	09/01/23	MT
Sector Update: Health Care	09/01/23	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Monday	09/01/23	MT
Rate Hike Clues, China Border Reopening Fuel Gains for US Equity Futures	09/01/23	MT
Top Premarket Gainers	09/01/23	MT
Amryt Pharma to be Acquired by Chiesi Farmaceutici	09/01/23	MT
Italy's Chiesi Farmaceutici to Buy Rare Disease-focused Amryt Pharma for $1.5 Billion	09/01/23	MT
Chiesi Farmaceutici S.p.A. entered into a definitive agreement to acquire Amryt Pharma plc from Athyrium Capital Management, LP, Highbridge Capital Management, LLC, Joe Wiley, Rory Nealon, Ray Stafford and others for $1.1 billion.	07/01/23	CI
Amryt Pharma Says Phase 3 Trial of Cholesterol Disorder Treatment Met Primary Endpoint; Shares Gain Pre-Bell	05/01/23	MT
Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH	05/01/23	CI
Amryt Says European Medicines Agency Committee Adopts Positive Opinion on Orphan Designation for Mycapssa	19/12/22	MT
Amryt Pharma Receives Approval for Mycapssa in Europe	05/12/22	MT
Amryt Announces European Commission Approves Mycapssa® for the Treatment of Acromegaly	05/12/22	CI
Amryt Pharma Says It Received New US Patent for Mycapssa	30/11/22	MT

Chart Amryt Pharma plc

Duration

Period

More charts

Company Profile

Amryt Pharma plc is a commercial-stage biopharmaceutical company. It is focused on acquiring, developing, and commercializing novel treatments for rare diseases. Its commercial business comprises three orphan disease products, such as metreleptin (Myalept/ Myalepta); lomitapide (Juxtapid/ Lojuxta), and oral octreotide (Mycapssa). Myalept is approved in the United States as an adjunct to diet as replacement therapy to treat leptin deficiency in patients with congenital or acquired generalised lipodystrophy (GL). Juxtapid is approved as an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the rare cholesterol disorder, homozygous familial hypercholesterolaemia (HoFH). Mycapssa is a combination of octreotide acetate and excipients, collectively called Transient Permeability Enhancer (TPE). Its development candidate, Oleogel-S10 (Filsuvez) is a treatment for the cutaneous manifestations of junctional and dystrophic (JEB and DEB) epidermolysis bullosa.

Sector

Pharmaceuticals

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
CSL LIMITED	-1.62%	89.22B
SAMSUNG BIOLOGICS CO.,LTD.	+2.24%	40.49B
BIOGEN INC.	-12.97%	32.79B
UCB	+63.62%	26.23B
BIOMARIN PHARMACEUTICAL INC.	-20.71%	14.52B
INCYTE CORPORATION	-7.31%	13.09B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.64%	11.5B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.60%	11.6B
SWEDISH ORPHAN BIOVITRUM AB	+5.47%	8.82B

Biopharmaceuticals